LexaGene featured in Boston Herald: “Testing for the coronavirus could be done in an hour without lab-trained technicians using a device the size of a Keurig coffee machine that a Boston-area biotech company is developing.”
LexaGene featured on ABC affiliate WCVB News Boston on how the company plans to help with better testing for the rapid detection of COVID-19.
LexaGene mentioned in New York Times article focusing on genomic testing efforts to combat COVID-19.
LexaGene CEO Dr. Jack Regan mentioned in Forbes article on the potential infection rate of COVID-19 and worldwide impact.
LexaGene CEO Dr. Jack Regan quoted as a virologist and influenza expert in the Boston Herald on the challenges of self-quarantine measures during the 2019 coronavirus outbreak.
Read local coverage of LexaGene’s development of a genetic analyzer to detect viruses like coronavirus.
Shortcomings in traditional culture testing leave the cannabis industry in search of methods that can enumerate or count the presence of microbes whether dead or alive. LexaGene CEO Dr. Jack Regan presents an alternative in the Cleanroom Technology article on LexaGene’s DNA-driven pathogen detection for cannabis-hemp products.
This Forbes full-length feature on LexaGene and our technology describes how LexaGene could be the next big medical breakthrough. > Read now.
LexaGene was mentioned in this Forbes article as a solution provider tackling the challenge of improving food safety and reducing recalls.
Digital Journal sits down with LexaGene CEO Dr. Regan to discuss the challenge of antibiotic resistance threats and how LexaGene’s LX Analyzer can help improve antibiotic stewardship.
LexaGene’s beta installation at CDX cannabis testing facilities featured in Cleanroom Technology. The article describes how LexaGene is bringing better detection to the cannabis testing market.
Boston Business Journal featured LexaGene in a story about how the company is trying to tackle possible under-reporting of EEE virus.
